Analysts expect LifeMD to report Q3 2026 revenue of $48.80 million and a loss of $0.14 per share, with the current stock price of $2.38 trading significantly below the $8.13 average analyst target. The primary focus for investors this quarter is the scale and margin profile of the Weight Management program, specifically the transition to branded GLP-1 medications which now represent 95% of new patient starts.
While the company recently rescheduled its formal conference call to November 12, market participants are looking for evidence of a return to positive adjusted EBITDA in the second half of the year. Despite an expected 19% year-over-year revenue decline, management's focus remains on high-value recurring subscribers and expanding pharmacy fulfillment capabilities.